A Quality-by-Design Approach to Upstream Bioprocess Interrogation and Intensification

Stephen Craven¹ and Ulrike Becken²*
¹ APC Ltd, Dublin, Ireland; ² Eppendorf AG Bioprocess Center, Juelich, Germany
* Corresponding author: becken.u@eppendorf.com

Abstract

Efficient biopharmaceutical process development relies on the Quality-by-Design (QbD) paradigm. QbD is a scientific, risk-based proactive approach to drug development that aims to have a full understanding of how the process and product are related. This knowledge is gained by process analytical technology (PAT). In this case study the Applied Process Company (APC) integrated external PAT and an APC-developed controller with an Eppendorf DASGIP® Parallel Bioreactor System. Online PAT measurement and control of the identified critical process parameters led to greater understanding and the streamlined optimization of a mammalian cell bioprocess. The study exemplifies the value of flexible bioreactor systems which allow ease of integration of third-party technology.

Introduction

Biopharmaceuticals represent a significant and growing sector of the pharmaceutical industry. The global biopharmaceutical industry is currently worth over 107 billion euros, according to research conducted by BioPlan Associates [1]. However, a lack of understanding of the process and product interdependencies potentially results in manufacturing challenges. Optimization of protein production based on empirical experimentation and quality testing of the end product often results in bioprocesses operating under suboptimal conditions and hence in extended cycle times, excessive raw material and utility requirements, and elevated numbers of process or product failures which together culminate in a high cost of manufacturing.

To ensure consistent drug quality and reduce batch-to-batch variability pharmaceutical companies and regulatory authorities aim to replace the “Quality-by-testing” with a “Quality-by-Design” strategy. In a QbD approach, critical quality attributes of the end product are defined and subsequently a production process is developed which aims at meeting those attributes. This involves identification of a design space, a range of experimental conditions within which variations in process parameters do not affect product quality. Prerequisite is the identification of critical process parameters by PAT that in the course of protein manufacturing are then monitored and, if needed, controlled.
The PAT required to support a QbD product may be simple or complex depending on the nature of the product and process used for its manufacture. Generally speaking, mammalian cell culture processes and the products, which they produce are complex, and hence, there are many challenges to implementing a PAT/QbD strategy. However, the potential benefits coupled with regulatory pressures are driving a strong interest in and an increased level of adoption in the biopharmaceutical industry. Biological processes are known to have a much higher level of variability than their chemical counterparts. PAT and QbD offer an avenue to better understand and control this variability, which has implications for the process economics, control and final product quality. Traditionally, temperature, pH, and dissolved oxygen are the main parameters measured and controlled online due to the availability of traditional, robust sensors. However, as technology advances, other process parameters such as cell density, cell viability, substrate concentrations, product and by-product concentration, dissolved carbon dioxide and biomarkers can now be measured and analyzed in real-time in an automated manner, although not yet routinely. The availability of real-time process information is of particular value in addressing the variability and unpredictability of animal cell cultures as it opens up the possibility of implementing advanced control strategies capable of directly impacting critical process parameters and critical quality attributes.

APC delivers chemical and bioprocess engineering solutions and technologies to enable streamlined development, optimization, and supply of new and existing chemical and biological entities. APC’s process development technology platform (BIOACHIEVE™) combines PAT technology, multivariate data analysis, process modelling, and advanced control strategies [2].

This application note describes the successful integration of external PAT with an Eppendorf DASGIP Parallel Bioreactor System using the Eppendorf’s software DASware analyze. The aim was to optimize the performance of a Chinese hamster ovary (CHO) mammalian cell bioprocess. In a previous study the glucose concentration was identified as a critical process parameter [3]. The objective of the following case study was to improve process performance by optimizing the glucose feed profile. By moving from the traditional bolus fed-batch to a continuous feeding fed-batch strategy, nutrient depletion should be prevented and a stable macro-environment for the cells should be established.

Material and Methods

Cell culture

CHO cells were cultivated in a glucose-free formulation of EX-CELL® CHO DHFR medium (Sigma-Aldrich® Co., LLC, USA) supplemented with 20 mM glucose, 4 mM glutamine, 1 µM methotrexate, 0.1 % (v/v) Pluronic® F-68 (Sigma-Aldrich Co., LLC, USA) and 10 mL/L penicillin-streptomycin (Sigma-Aldrich Co., LCC, USA). Cells were cultivated for...
7 to 9 days at 37°C using a four-fold DASGIP Benchtop Bioreactor System for cell culture equipped with 2.5 L (working volume) DASGIP Benchtop Bioreactors (Eppendorf AG, Germany) (figure 1). Cultures were agitated at 120 rpm. The pH was controlled at 7.2 using 1 M NaOH and CO₂ gas, respectively. Air saturation was set to 50 % and controlled using air and oxygen supplied via a sparger.

**Offline measurement of process parameters**

Cell density and cell viability were determined offline using a Cedex® HiRes system (Roche Diagnostics® GmbH, Germany). Offline measurements of glucose concentrations were performed using an enzymatic assay kit (Megazyme® International Ireland Ltd.).

**Integration of external PAT and in-house developed controllers**

Figure 2 illustrates the integration of external PAT and an in-house developed controller with an Eppendorf DASGIP Parallel Bioreactor System. Online measurements of glucose concentration were performed by Raman spectroscopy. A RamanRxn2 Multi-channel Raman analyzer (Kaiser Optical Systems, Inc., USA) was integrated with the DASGIP system using DASware analyze software (Eppendorf AG, Germany). DASware analyze utilizes an object linking and embedding for process control (OPC) communication protocol, an industry standard which facilitates the communication of devices from different manufacturers. To translate the Raman spectra into concentration information, chemometric partial least squared calibration models were developed using the SIMCA® multivariate data analysis package (MKS Umetrics AB, Sweden).

To maintain the glucose concentration close to the set-point an APC-developed model predictive controller (MPC) algorithm was integrated via bidirectional OPC communication. The essence of MPC is to optimize forecasts
of process behavior. This forecasting is accomplished with a process model, and, therefore, the model is an essential element of an MPC controller. Based on online readings of the identified critical process parameters, the model is used to calculate optimal feed rates for set-point maintenance. MPC facilitates to proactively counteract deviations from the set-point and to simultaneously control multiple process parameters and is hence especially suited to ensure constant culture conditions in multivariate bioprocesses.

The MPC actuated a DASGIP MP8 multi pump module (Eppendorf AG, Germany) to execute continuous glucose feeding.

**Bolus fed-batch and continuous fed-batch glucose feeding**

The glucose concentration was adjusted using a feed medium consisting of 653.6 mM glucose, 58.8 mM glutamine and 58.8 g/L soy protein hydrolysate dissolved in glucose-free EX-CELL CHO DHFR- medium.

Two fed-batch feeding strategies were investigated in the study. The first was a fed-batch culture manually fed with bolus additions, at 24 h intervals, the volume of which was proportional to offline integral viable cell density measurements for the previous 24 h interval.

The second regime was a continuous feed, the rate of which was determined and adjusted automatically using a model predictive controller and Raman-determined glucose values to keep the glucose concentration in the bioreactor at a set-point of 11 mM throughout the culture.

**Results and Discussion**

Using the DASware analyze software a RamanRxn2 Multi-channel Raman analyzer (Kaiser) and an APC-developed MPC algorithm were successfully integrated with an Eppendorf DASGIP Parallel Bioreactor System. The glucose concentration in the CHO mammalian cell culture was determined online using Raman spectroscopy coupled with chemometric partial least squared modeling. The offline results determined via an enzymatic assay were highly comparable to the results obtained online by Raman spectroscopy (figure 3A, 3B).

Overall, the continuous feeding fed-batch bioprocess resulted in an increase in peak viable cell density and the integral of the viable cell density (figure 3C, 3D) which is directly related to increased titre.

**Conclusion**

The Eppendorf DASGIP Parallel Bioreactor System was a suitable host for APC’s BIOACHIEVE process development technology platform, which APC applies to upstream bioprocesses. The DASGIP system facilitated the ease of integration of external PAT and transfer of this information to and from APC-developed controllers. This allowed optimization of the process performance based on greater process understanding, ultimately delivering improvements in cell growth. This case study exemplifies the value of increased process understanding and control in biopharmaceutical manufacturing. Advancements in sensor technology and data analysis facilitate the ability to control the identified critical process parameters to their respective target levels and thus optimize the critical quality attribute design space.

To apply the QbD approach to upstream bioprocess development, bioreactor systems which allow smooth integration of external sensors and controllers are crucial.
Literature

### Ordering information

<table>
<thead>
<tr>
<th>Description</th>
<th>Order no.</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>DASGIP® Parallel Bioreactor System for Cell Culture</strong>, max. 50 sL/h gassing</td>
<td></td>
</tr>
<tr>
<td>4-fold system with Bioblock</td>
<td>76DG04CBB</td>
</tr>
<tr>
<td>8-fold system with Bioblock</td>
<td>76DG08CBB</td>
</tr>
<tr>
<td>16-fold system with Bioblock</td>
<td>76DG16CBB</td>
</tr>
<tr>
<td>4-fold system, benchtop</td>
<td>76DG04CSU</td>
</tr>
<tr>
<td>8-fold system, benchtop</td>
<td>76DG08CSU</td>
</tr>
<tr>
<td>16-fold system, benchtop</td>
<td>76DG16CSU</td>
</tr>
<tr>
<td><strong>DASWare® control</strong>, incl. PC, OS, and licenses</td>
<td></td>
</tr>
<tr>
<td>for 4-fold DASGIP® system</td>
<td>76DGC54</td>
</tr>
<tr>
<td>for 8-fold DASGIP® system</td>
<td>76DGC58</td>
</tr>
<tr>
<td><strong>DASWare® control professional</strong>, incl. PC, OS, and licenses</td>
<td></td>
</tr>
<tr>
<td>for 4-fold DASGIP® system</td>
<td>76DGC5P4</td>
</tr>
<tr>
<td>for 8-fold DASGIP® system</td>
<td>76DGC5P8</td>
</tr>
<tr>
<td><strong>DASWare® analyze</strong>, OPC client professional incl. 1x tunneller lic. (OPC DA e.g. for ext. analyzer with autosampler)</td>
<td></td>
</tr>
<tr>
<td>for 4 vessels</td>
<td>76DWANA4P</td>
</tr>
<tr>
<td>for 8 vessels</td>
<td>76DWANA8P</td>
</tr>
<tr>
<td>for 16 vessels</td>
<td>76DWANA16P</td>
</tr>
</tbody>
</table>

For information on the APC BIOACHIEVE™ platform please see www.approcess.com

Your local distributor: [www.eppendorf.com/contact](http://www.eppendorf.com/contact)
Eppendorf AG · 22331 Hamburg · Germany
ependorf@eppendorf.com · www.eppendorf.com

www.eppendorf.com

EX-CELL® and Sigma Alrich® are registered trademarks of Sigma-Aldrich Co. LLC., USA. Megazyme® is a registered trademark of Megazyme International Ireland Ltd., Ireland. CEDEX® and Roche Diagnostics® are registered trademarks of Roche Diagnostics GmbH, Germany. FluoroChrom® is a registered trademark of BASF Corporation, USA. SIMCA® is a registered trademark of MKS Utrosmics AB, Sweden. BIOACHIEVE™ is a trademark of APC Ltd., Ireland. RamanRxn™ is a trademark of Kaiser Optical Systems Inc., USA. Eppendorf® and the Eppendorf logo are registered trademarks of Eppendorf AG, Germany. DASGIP® and DASWare® are registered trademarks of DASGIP Information and Process Technology GmbH, Germany. U.S. Design Patents are listed on www.eppendorf.com/ip.

All rights reserved, including graphics and images. Copyright © 2015 by Eppendorf AG.